 |
11 Diseases |  |
0 Trials |
|
0 Trials |  |
29 News |  |
- || Review, Journal: Cognitive Impairment in Parkinson's Disease: An Updated Overview Focusing on Emerging Pharmaceutical Treatment Approaches. (Pubmed Central) - Oct 28, 2023
In this updated overview, we aim to cover the clinical aspects of the spectrum of PD-related cognitive impairment and discuss recent evidence on emerging treatment approaches that are under investigation at a preclinical and clinical level. Finally, we aim to provide additional insights and propose new ideas for investigation that may be feasible and effective for the spectrum of PD-related cognitive impairment.
- | landipirdine (SYN120) / Acorda
Journal: Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial. (Pubmed Central) - Sep 11, 2023
P2
SYN120 was adequately tolerated, mild worsening of motor symptoms was noted and it did not improve cognition in PDD patients. Its potential benefits for cognitive activities of daily living and apathy warrant further study.
- landipirdine (SYN120) / Acorda
COMBINED TWO-PHOTON-BASED IMAGING OF STRIATAL DOPAMINERGIC FIBERS AND INTEGRATIVE ASSESSMENT OF SYNAPTIC MARKERS ALLOWS TO STAGE RETROGRADE DEGENERATION IN ?-SYNUCLEIN TRANSGENIC MICE (On-Demand Oral Gallery B) - Dec 23, 2022 - Abstract #ADPD2023ADPD_745;
Moreover, they support that the initial phase of pathological ? -syn-induced dopaminergic dysfunction is characterized by dopamine turnover perturbation with accumulation of dysfunctional DAT and that these pre -degenerative synaptic alterat ions can initiate nigrostriatal deafferentation.
- | landipirdine (SYN120) / Acorda
Journal: Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson's disease. (Pubmed Central) - Apr 8, 2022
-syn-induced dopaminergic dysfunction is characterized by dopamine turnover perturbation with accumulation of dysfunctional DAT and that these pre -degenerative synaptic alterat ions can initiate nigrostriatal deafferentation. Dopamine inhibits canonical, non-canonical, and α-syn-mediated activation of the NLRP3 inflammasome in primary human microglia, as does high extracellular K. We suggest that dopamine serves as an endogenous repressor of the K efflux-dependent microglial NLRP3 inflammasome activation that contributes to dopaminergic neurodegeneration in PD, and that this reciprocation may account for the specific vulnerability of these neurons to disease pathology.
- || Review, Journal: Treatment of Parkinson's Disease with Cognitive Impairment: Current Approaches and Future Directions. (Pubmed Central) - May 1, 2021
There is growing research supporting exercise in the treatment of PD-MCI, but most non-pharmacological approaches have insufficient evidence for use in PD-MCI (cognitive rehabilitation, deep brain stimulation, transcranial direct current stimulation, transcranial ultrasound, vestibular nerve stimulation) and PDD (cognitive intervention, deep brain stimulation, transcranial alternating current stimulation, transcranial ultrasound, temporal blood brain barrier disruption). Research is needed for both disease-modifying and symptomatic treatments in PD cognitive impairment.
- | methylphenidate tablet / Generic mfg.
Journal: Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate. (Pubmed Central) - Mar 31, 2021
Our observations indicate that the motor-stimulating effect of MPH can be positively fostered in the presence of α-syn/Syn III co-aggregation. This evidence holds significant implications for PD and ADHD therapeutic management.
- || Review, Journal: Serotonin Type 6 and 7 Receptors as a Novel Therapeutic Target for the Treatment of Schizophrenia. (Pubmed Central) - Nov 6, 2020
SGS-518, ABT-354, Lu AE58054, SB-742,457, S-518, AVN-211, AVN-322, SYN-114 and SYN-120 are serotonin 6 receptor antagonists and aripiprazole-controlled release serotonin 7 receptor agonists under clinical trial for schizophrenia. Thus, research on novel drugs that act on serotonin 6 and 7 receptors likely facilitates the intervention into schizophrenia patients seeking better quality of life in the future.
- |||| landipirdine (SYN120) / Acorda
Trial completion: SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE) (clinicaltrials.gov) - Jan 19, 2018
P2, N=80, Completed, Sponsor: Biotie Therapies Inc.
Thus, research on novel drugs that act on serotonin 6 and 7 receptors likely facilitates the intervention into schizophrenia patients seeking better quality of life in the future. Active, not recruiting --> Completed
- ||| landipirdine (SYN120) / Acorda
Enrollment closed: SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE) (clinicaltrials.gov) - Aug 3, 2017
P2, N=80, Active, not recruiting, Sponsor: Biotie Therapies Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || landipirdine (SYN120) / Acorda
Trial primary completion date: SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE) (clinicaltrials.gov) - Sep 13, 2016
P2, N=80, Recruiting, Sponsor: Biotie Therapies Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> Dec 2017
- |||| landipirdine (SYN120) / Acorda
Enrollment open: SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE) (clinicaltrials.gov) - Dec 25, 2014
P2, N=80, Recruiting, Sponsor: Biotie Therapies Inc.
Trial primary completion date: Dec 2016 --> Dec 2017 Not yet recruiting --> Recruiting
- ||||| landipirdine (SYN120) / Acorda
New P2 trial: SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE) (clinicaltrials.gov) - Oct 10, 2014
P2, N=80, Not yet recruiting, Sponsor: Biotie Therapies Inc.